Kiniksa Pharmaceuticals
KNSA
101 hedge funds and large institutions have $332M invested in Kiniksa Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 37 increasing their positions, 26 reducing their positions, and 19 closing their positions.
42% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 26
5% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 19
0.03% more ownership
Funds ownership: 89.28% → 89.31% (+0.03%)
1% less funds holding
Funds holding: 102 → 101 (-1)
11% less call options, than puts
Call options by funds: $3.15M | Put options by funds: $3.54M
17% less capital invested
Capital invested by funds: $402M → $332M (-$70M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$8.09M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$6.25M |
| 3 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$5.29M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.88M |
| 5 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$4.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$15.3M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$11.1M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$5.58M |
| 4 |
State Street
Boston,
Massachusetts
|
-$3.39M |
| 5 |
Millennium Management
New York
|
-$2.87M |
KNSA Hedge Fund Activity: Q3 2021 in Review
101 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q3 2021, worth a combined $332M — down 17% from $402M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new KNSA positions and 19 closed out — a net gain of 1 holder — while 37 added to existing stakes and 26 trimmed.
The largest buyer was BlackRock, adding an estimated $8.09M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $15.3M sold.
- 101 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q3 2021, down from 102 in Q2 2021.
- Funds reported $332M of Kiniksa Pharmaceuticals stock for Q3 2021, down 17% quarter-over-quarter.
- 20 funds opened new Kiniksa Pharmaceuticals positions in Q3 2021 and 19 closed out, a net change of +1 holder.
- The largest Kiniksa Pharmaceuticals buyer in Q3 2021 was BlackRock, an estimated $8.09M added.
- The largest Kiniksa Pharmaceuticals seller in Q3 2021 was Janus Henderson Group, an estimated $15.3M sold.
Based on aggregated 13F filings for Q3 2021.